In the assessment of 12-month price targets, analysts unveil insights for Alnylam Pharmaceuticals, presenting an average target of $420.41, a high estimate of $570.00, and a low estimate of $333.00.

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $406.0, a high ...

Fintel reports that on August 4, 2025, Oppenheimer upgraded their outlook for Alnylam Pharmaceuticals (NasdaqGS:ALNY) from ...

Fintel reports that on August 4, 2025, Wolfe Research upgraded their outlook for Alnylam Pharmaceuticals (NasdaqGS:ALNY) from ...

Alnylam Pharmaceuticals, Inc. ( NASDAQ:ALNY ) shareholders will have a reason to smile today, with the analysts ...

Second Quarter 2025 Results Key Financial Results Revenue: US$773.7m (up ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter ended June 30, 2025 and reviewed recent ...

The FDA has approved inclisiran (Leqvio) for first-line use in lowering LDL cholesterol, even without combining it with ...

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the enrollment of the first participant in ECLIPSE 3. All three trials ...

Detailed price information for Baxter International Inc (BAX-N) from The Globe and Mail including charting and trades.

Detailed price information for Alnylam Pharmaceuticals (ALNY-Q) from The Globe and Mail including charting and trades.

Apollo Global Management Inc (APO) is expected to report $1.64 for 2Q. Archer Daniels Midland Co (ADM) is expected to report $0.83 for 2Q. Archrock Inc (AROC) is expected to report $0.38 for 2Q.